A Study of Gaboxadol in Primary Insomnia

A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00209963

Enrollment

600

Registered

2005-09-21

Start date

2003-06-30

Completion date

2005-03-31

Last updated

2007-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Keywords

Primary insomnia

Brief summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Detailed description

To obtain long-term safety and tolerability data with gaboxadol.

Interventions

DRUGGaboxadol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* patients with Primary insomnia

Design outcomes

Primary

Measure	Time frame
Long-term safety in gaboxadol.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026